Current Region: North America
Your selections will be saved and used to recommend products based on your interests.
Sep 24 2013 8:00AM - Sep 25 2013 5:00PM | Barr Al Jissah Hotel
P.O. Box 644
New Middle East and European speakers announced! Download the pdf now for details of the programme
This is the 10th DIA Middle East Regulatory Conference in partnership with the Middle East Regulatory Network (MERN), an ad hoc regional network of the EFPIA (European Federation of Pharmaceutical Industries and Associations). The MERN works in partnership with regulatory authorities and the pharmaceutical industry in the Middle East to develop legislation and regulatory practices that enable patients to have access to good quality medicines, including innovative medicines.
This Conference has been held every two years since 1996, and has now become an important forum related to the provision of healthcare in the region, with the aim of achieving real improvements in access to new and improved medicines and therapies for the population in the Middle East region.
It provides a forum for all participants to contribute to active discussion and identify actions to expedite access of valued innovative medicines to Middle Eastern patients.
The conference offers the opportunity for key stakeholders active in the region, including representatives from ministries of health, local and multi-national pharmaceutical companies, to meet to exchange views, discuss topics of interest and identify actions to increase patient access to new and improved medicines and therapies.
If you register for both The 10th Middle East Regulatory Conference (MERC) 2013 and The ICH Endorsed Pharmacovigilance Training Course, you will receive 50% off the ICH Endorsed Pharmacovigilance Training Course fee - this offer is only available by emailing email@example.com. Please note you have to register for both at the same time to be eligible to receive the discount.
DIA has blocked a limited number of rooms at the following hotel:
Shangri-La Barr Al Jissah HotelP.O. Box 644Muscat, Post Code 113Sultanate of Oman
Tel: 00968 2477 6666Fax: 00968 2477 6677 Website: http://www.shangri-la.com/muscat/barraljissahresort/
at the rate of: Al Bandar Deluxe Room RO 70.00 single occupancy and RO 80.00 double occupancy inclusive of breakfast buffet, plus service charge and taxes of 17%.
To make your reservation please use this booking form:
Hotel booking form
Important: Demand is high for accommodation during the conference dates, we encourage you to reserve your hotel room before end of July. Reservations received after this date will be subject to hotel availability and room rate may vary.
Cancellation: No show charges to apply without a notification from the Hotel. Booking cancelled after 23rd July 2013 will be charged 100% cancellation fee.
Arriving passengers who are eligible for Visa on Arrival are able to obtain and make their visa payments at the Travelex Foreign Exchange bureau located in the immigration arrivals hall, payment can be accepted in most currencies or by credit card, an automatic receipt will be issued to the traveller this receipt is then presented at the immigration desk.
For more details please visit: http://www.omanairports.com/visaonarivals.asp
All other guests are kindly requested to apply for their visa directly through the Online Visa Application Service of the Royal Oman Police by using the following link: http://www.rop.gov.om/visa/english/onlineservices_visaapplication_main.aspx.
Should you have any question, please contact firstname.lastname@example.org
Ministry of Health, Egypt
Supervision Director in Pharmaceutical Affairs Food and Drug Organization of MoHMinistry of Health, Iran, Islamic Republic of
Regulatory Affairs DirectorJanssen-Cilag, Saudi Arabia
Regulatory Affairs DirectorAbbott Laboratories S.A., United Arab Emirates
Regulatory Affairs ManagerJanssen Cilag NEWAAT, Lebanon
Head National Health Regulatory Authority, Bahrain
Executive Director of Licensing DepartmentSaudi Food and Drug Administration, Saudi Arabia
Director General of Pharmaceutical Affairs & Drug ControlMinistry of Health, Oman
General DirectorJordan Food and Drug , Jordan
Scientific Office ManagerJanssen Cilag, Egypt
Regulatory Affairs ManagerEli Lilly Export S.A., Switzerland
Director Regulatory Affairs InternationalBiotest AG, Germany
MEA Regional and Market Support DirectorAstraZeneca, United Kingdom
Associate Director Global Regulatory AffairsGruenenthal GmbH, Germany
Eisai Ltd., United Kingdom
Reg. AfairsChiesi Farmaceutici SPA, Italy
GlaxoSmithKline R&D, UK, United Kingdom
Executive Director, Regulatory Policy, EU and Most of WorldMerck Sharp & Dohme Inc., Belgium
Janssen Johnson&Johnson PRD, United Kingdom
Manager, Global Emerging Markets - International Regulatory AffairsBiogen Idec Limited, United Kingdom
Head of Regulatory Affairs BayerHealth Care, United Arab Emirates
Regulatory Affairs DirectorTEVA Santé, France
Regulatory Director M.S.D., United Arab Emirates
Manager Global Regulatory Affairs - InternationalUCB Headquarters, Belgium
MEA Regulatory Affairs Director Bristol-Myers Squibb, United Arab Emirates
Regulatory Affairs – Europe RegionSanofi, France